Noxopharm (ASX:NOX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Noxopharm (ASX:NOX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
2026 AGM Letter of Access, Notice of Meeting and Proxy
Appendix 4G and Corporate Governance Statement
Annual Report to shareholders
Noxopharm reports clinical progress but flags material funding uncertainty
FDA feedback supports SOF-SKN Phase II plans
FDA supports Noxopharm's planned Phase II pathway for SOF-SKN lupus therapy
Audited Financial Statements
Noxopharm reports $4.46m loss and material going-concern uncertainty despite Sofra platform progress
SOF-SKN to progress to extension study in CLE patients
Investor Presentation September 2026
Novel oligonucleotides data presented at Options Conference
Noxopharm's Sofra oligonucleotides show promise in reducing inflammation from next-gen mRNA vaccines
Appendix 4E - Preliminary Financial Report
New preclinical data supports immuno-oncology approach
Noxopharm's Sofra technology shows immune activation potential in preclinical cancer studies
New study further validates Noxopharms cancer pipeline
Quarterly Activities/Appendix 4C Cash Flow Report
Noxopharm advances cancer and autoimmune drug programs with Sofra platform; reports cash position and funding plans
